Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: xomadog2 who wrote (9958)	5/14/1999 11:09:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

You are correct, but I am not talking about results. The phony self imposed censorship of the pre established mortality target. The FDA did not tell XOMA it could not tell shareholders of its existence. XOMA only claims the DSMB said not to tell shareholders. My question is since when does a DSMB butt into what is a shareholders informational area. No one has ever been able to explain how release of this number would have in any way impacted the clinical trial. Second, the FDA does not mandate waiting to release results, after all the analysis has been done to an appropriate scientific forum. The partial hep. P I concluded in 97 and in theory we are still waiting for an appropriate forum for this information to be released. If XOMA had not been chosen to run P III for GNE would it still have received a 25% interest in hu1124???? That was the big deal. I talk to XOMA and posters, so? I do not ask XOMA a lot of questions. I have spent most of my time with Martin pushing for better and faster disclosure to all shareholders rather than attempting to garner information for myself. If I do hear something other than what I asked I generally post it. Knowing about the pre established mortality level was important to making good decisions about when and how much to invest in XOMA. Not knowing it even existed let investors believe the trial could end early. Now with the trial over, XOMA does not even let us know what that target, (NOT A RESULT) was???? Give me a break.

To: xomadog2 who wrote (9958)	5/14/1999 11:10:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

George, I have to agree with xomadog 100% here.>>>>>>>>>>>>>>> >>>>"The expectation to have results given out to the shareholders is unrealistic. The company is "locked" in to a process of approval,that, to blab the results around without the consent of the FDA would be devastating. The company is not "allowed" based on an established quid pro quo with the FDA to do anything about giving the news to shareholders first with regard to results of trials." As such, I opened my annual report packages, totaled my shares (to see what I had) and vote all yes's via internet. I did abstain on 25 shares though as a gesture. I dont really care for proposal #2, and am really wary of proposal #3 but the benefits probably do outway the risks. I do think management is good and acting in a generally responsible manner. If (big if) they get to market you should kiss their feet. All IMO, standard K disclaimers.